BPC-157 for a herniated disc: what the evidence reaches, and what it does not

Seven in ten of these clear on their own, and that is the number anything has to beat

Before any compound: a meta-analysis pooled 31 studies covering 2,233 people whose herniated discs were managed without surgery. The displaced disc material was reabsorbed in 70.39% of them. The rate ran 87.77% where a fragment had fully broken free, 66.91% for an extrusion, 37.53% for a protrusion, 13.33% for a bulge. Most of the shrinking happened inside the first six months.

And a randomised trial in 283 people with severe leg pain lasting 6 to 12 weeks compared early surgery against continued conservative care. Surgery took the leg pain away faster. At one year, the probability of feeling recovered was 95% in both arms.

Hold those two numbers against everything below. If you start a compound today and feel better in three months, the honest reading is that you are inside the seven-in-ten who were going to improve anyway. Nothing on this page separates you from that group, because no trial has ever been run that could.

Your problem is at least three problems, and a compound can only reach two of them

The first is space. Disc material is sitting where a nerve root needs to be. That is what the scan measures, and the only two things that remove it are your own body digesting the fragment over months and a surgeon cutting it out. No compound in any species has been shown to shrink a herniation.

The second is chemistry. The material that leaked out is not inert. Mice given disc material placed against a nerve root developed lasting leg pain and damage to the nerve cells, with no squeezing involved at all — the inflammatory signal did it.

The inflammatory enzyme measured in human herniated disc material runs 20 to 100,000 times more active than the same enzyme measured from any other source in the literature.

The third is the nerve itself. A root that has been squeezed and chemically burned for weeks has damaged fibres, and that is what produces the numbness, the pins and needles and the weak foot. Nerve fibres regrow at roughly a millimetre a day, which is why that part of the recovery lags the pain by months.

The claim on the table is that this compound reaches the second and third problems and not the first. Read the next two sections deciding whether the animal work supports even that much.

Nobody has put this compound near a spinal disc, in any species

A systematic review in orthopaedic sports medicine screened 544 articles from 1993 to 2024 and kept 36 studies. Thirty-five were animal or dish work. One was clinical. The tissues were muscle, tendon, ligament and bone.

There is no disc study. Not a rat disc, not a rabbit disc, not a disc in a dish. The tissue that is actually causing your pain has never been exposed to this compound in a published experiment. Every argument for using it on a disc is an argument by analogy from a different tissue, and analogies from tendon to disc are weak: a tendon has a blood supply and a disc, after about age twenty, has almost none.

What the rats did show, and which of your three problems it lands on

Rat Achilles tendon torn off the bone. Treated animals healed with more strength at the tendon-to-bone join, and the same experiment showed a steroid drug made healing worse while the compound cut that damage back.

Rat ligament cut through. Better function, better mechanical strength, better tissue on the slide, at both a microgram and a nanogram dose.

Rat sciatic nerve cut and repaired. The nerve regrew faster and the leg worked better than in untreated animals. This is the single finding on this page that touches nerve tissue, and it is a cut nerve trunk in a rat leg, not a chemically inflamed nerve root in a human spine.

Rat spinal cord crushed. Treated animals recovered movement, starting at the tail, and held it out to a year.

Tendon cells in a dish moved to the wound edge faster as the dose went up, and made more of the receptor that growth hormone docks into.

Map that onto your three problems. Space: nothing, in any of it. Chemistry: the nerve and cord work is consistent with the inflamed-nerve part of your pain, in rodents. Structure: the tendon and ligament work is about a tissue you also injured, because a herniation almost always comes with a torn ring and months of guarding, but it is not about the disc.

The steroid shot you probably already had is the strongest single link here

Most people arrive at this question having already had an epidural or a joint steroid injection, or a course of an anti-inflammatory tablet. Two separate rat studies found a corticosteroid made healing worse in tendon and in muscle, and that this compound reversed that damage. In the muscle study the reversal was described as complete.

And in a rat model of anti-inflammatory drug poisoning, diclofenac at 12.5 mg/kg for three days wrecked the stomach, gut and liver and progressed to brain swelling. The compound blocked that whole cascade, given either by injection or dissolved in the drinking water, at both 10 µg/kg and 10 ng/kg.

Read that carefully. It is a protection finding about the drugs you are already taking, not evidence that the combination heals a disc faster. What it does settle is that the medicine most likely to already be in your system is not, in rats, a documented conflict.

Fifteen minutes in the blood, which is what decides the schedule

The only measurements of what a body does with this compound come from rats and beagles. Average time to clear half of it: 15.2 minutes. Into a vein in dogs: 5.27 minutes. Peak in the blood three minutes after an injection into muscle. The fraction reaching the blood after an injection into muscle was 14–19% in rats and 45–51% in dogs.

Two things follow for a daily plan. A compound gone that fast is not working by holding a level in your blood, so splitting a daily dose beats taking it all at once, and a once-weekly schedule has no argument behind it. None of these numbers has ever been measured in a person.

Turning a 10 mg vial into a number of marks on a barrel

The powder arrives sealed. You add bacteriostatic water — sterile water with 0.9% benzyl alcohol in it, which is the preservative that lets you put a needle back into the same vial for weeks. Plain sterile water dissolves it fine but makes the vial a one-time proposition.

The measuring device is a U-100 insulin syringe: 100 marks to a millilitre, so one mark is 0.01 mL. Two lines give you every conversion.

• Micrograms per mL = micrograms in the vial ÷ mL of water added.
• Micrograms per mark = that number ÷ 100.

A 10 mg vial holds 10,000 mcg. Add 3 mL and you have 3,333 mcg/mL, which is 33.3 mcg per mark. A 250 mcg dose is 250 ÷ 33.3 = 7.5 marks.

Adding more water does not add or remove peptide. It only changes how many marks carry a given dose. Below about five marks per dose, misreading the barrel starts to matter more than the dose does, which is the argument for putting 3 mL rather than 2 mL into a 10 mg vial.

Once mixed and kept at 2–8 °C, the vial has about four weeks in it, and that limit comes from the preservative rather than the peptide. Do not shake it and do not freeze it after mixing — both tear the peptide chains apart and make them clump, and clumping is exactly the trigger FDA named for the immune system reacting to an injected peptide.

Where the needle goes was never answered by the animal work

Every rat study injected either into the belly cavity or into a muscle far from the injury, and the healing still showed up at the wound. Nobody ran the experiment that compares injecting at the site against injecting anywhere else. So the widespread instruction to inject next to your spine rests on nothing published, and the people in the counted record below who got results injecting into a thigh or a glute are evidence against it mattering much.

Where it stands legally, checked 4 August 2026

FDA placed the compound in the bulk-substance bucket flagged for significant safety risk, which is what stopped compounding pharmacies from making it.

On 23 July 2026 the agency's own Pharmacy Compounding Advisory Committee voted against that position: eight yes, six no, one abstention. Reporting on the meeting noted that most of the yes votes came from members with peptide-industry ties. An advisory vote changes no rule by itself.

It is on the 2026 World Anti-Doping Agency prohibited list, in the class covering substances with no approval for human use, banned at all times in and out of competition.

The only registered trial with a person and an injury in it is a Phase 2 study in acute hamstring strain, which is muscle, not disc, and had not reported when this page was checked.

The one safety measurement in people is a pilot infusion of up to 20 mg into a vein in two healthy adults, with no adverse effects recorded. Two people is a safety signal about a single infusion, not about eight weeks of daily injection.

Twenty-four people with a spine problem said what happened, and here is the count

Method: searched old.reddit.com for "bpc 157 herniated disc", "bpc 157 sciatica" and "bpc157 disc bulge", read 18 threads in full, pulled 113 comments that name the compound, and kept the ones where a named account described their own lumbar or cervical spine problem and what happened. Twenty-four had a stated outcome. Two more had started too recently to count. That is the denominator; everything else in those threads was sourcing questions, dosing questions and injuries in other body parts.

Sixteen said it helped. The most detailed is an L5/S1 herniation treated with about 600 mcg a day for two and a half months, injected into the upper glute rather than the back, with no physical therapy at all — pain-free at the one-year mark, with the caveat added later that a nerve sensation in the leg came back after returning to Muay Thai, and "spinal discs require a good amount of time to fully heal."

Speed varied wildly. One person with L3–L5 bulging discs on 250 mcg of the compound plus 250 mcg of TB-500 twice a day wrote on day five that "the chronic pain is melting away, as of day three." Another, six years into an L4/L5 herniation with leg pain, reported at four days that a four-hour drive produced no pain for the first time. At the other end, one person with seven herniated discs wrote at 32 days that they had not felt this much relief in years, and another took eighteen months to recover without surgery while also doing physical therapy and taking collagen.

Almost every one of the sixteen was doing something else at the same time. TB-500 in most of them, physical therapy in several, a steroid injection in one, gabapentin in one, red-light therapy in one, weight loss in one. Three were reporting after surgery — one after a microdiscectomy that left them with a dropped foot, who wrote that five weeks of the pair "healed me". None of the sixteen is a clean read on this compound alone.

Two said it worked and then stopped working when they stopped taking it. One: six weeks of it "lowered the inflammation enough for life to be manageable. I was able to lift weights and stuff again. A week after running out of BPC-157 the pain came back completely. If not worse than before." The other finished a twelve-week run and found the pain returned, though not to where it had been.

That pattern is worth more attention than any of the enthusiastic reports, because it is what you would expect from something quieting inflammation around an irritated nerve rather than repairing anything. Relief that ends with the injections is relief, not repair.

Five said nothing happened. One with an L5/S1 herniation since age eighteen injected into their own back for three months and "couldn't tell you that it made any difference." One with an L3/4 bulge and an L5/S1 herniation ran the compound at 250 mcg a day with 5 mg of TB-500 a week for six weeks and had "zero noticeable difference in back pain over 6 weeks" — a dose at the bottom of the common range, which is the obvious objection to that one. One with two bulging discs tried it on several separate occasions and it did not help. One never injected anywhere near the back and said it did not do much. One said they noticed nothing and wondered aloud whether they had run it long enough.

One got worse, in a specific and checkable way. Two weeks in, their prescription pain medication stopped working. They stopped the compound and the medication started working again within 24 to 36 hours. That is a reported interaction with an opioid painkiller, from one person, uncontrolled, and it is the only harm report in the set that is about the spine problem rather than about the compound in general.

One further account belongs here and is not in the count. A person with multiple herniated discs from a car crash, with a graduate degree in kinesiology, who had taken this compound for other injuries, attributed her own recovery to a different peptide entirely and argued that this one "primarily targets soft tissue and ligament repair, which may be less directly effective in regenerating the disc structure itself." That is the same objection the missing disc study raises, made by someone who used the compound and did not credit it.

What the count settles and what it does not. Sixteen out of twenty-four is a high hit rate, and it is also exactly what you would get from a condition where seven in ten people improve without doing anything, in a population that self-selected by buying an expensive compound and posting about it. Nobody posts a thread called "I bought it and nothing happened", which is why the five negatives matter more than their share suggests. The two relapse reports are the most informative thing in the whole set, and no trial exists that would resolve them.

What would have to change for any of this to be settled

One rat study putting the compound near a damaged disc would tell you whether the analogy from tendon holds. One trial randomising people with a confirmed extrusion to the compound or a placebo, measuring leg pain at six weeks and the fragment on a scan at six months, would separate it from the 70% who resorb anyway. Neither exists, neither is registered, and the only trial running is in hamstrings.